‘Touch starvation' is an epidemic among this age group — here's what parents should be doing about it, experts urge
Young boys are reportedly feeling deprived of physical touch and affection, also known as 'touch starvation' — which can have a major impact on their emotional and social well-being.
'The bottom line: touch keeps you alive. It's crucial,' Michael Thompson, PhD, a clinical psychologist specializing in children and families, told Parents.com in an interview.
Experts like Thompson stressed the importance of positive touch for healthy development — especially for young men who are often exposed to toxic masculinity at a young age.
'Boys are already being socialized, whether parents know it or not. It's happening everywhere around them from the moment boys are exposed to the world, but particularly when they are exposed to media,' Matt Englar-Carlson, a men's mental health researcher and Chair of the Department of Counseling at California State University Fullerton, also told the outlet in the same interview.
Oftentimes, when young boys grow up without a healthy example of physical touch, it can come out in not-so-appropriate ways, like roughhousing with their peers.
Adults will often view this sort of playful teasing amongst young men as 'boys will be boys' — but it actually indicates that something more serious might be going on.
Iritability, anxiousness, social withdrawal or difficulty calming down are other tell-tale signs that a young male is suffering from touch starvation.
A 2016 study pointed out that young boys who were exposed to healthy physical touch when growing up reportedly had lower levels of depression and healthier romantic relationships when they were older.
Yet, according to a recent Gallup poll, American Gen Z and millennial men are reportedly the loneliest group — which proves that the majority of young boys are not being shown examples of positive physical touch when growing up.
To combat this growing epidemic, Thompson and Englar-Carlson suggested to the outlet some helpful ways parents can reintroduce healthy physical touch into their sons' lives.
One way is to use touch in a calming manner when a young boy is upset over something.
They also suggested that parents talk to their son about the type of touch they prefer — whether it be a hug, putting their arm around them, or giving them a soothing rub on the back.
The experts also said to discuss boundaries around physical touch with sons to learn what they feel comfortable with.
And if a parent senses that their son is not ready for a school drop-off hug just yet, they suggested saying something along the lines of, 'I need to hug you. Is there a place I can do it where you'd feel comfortable?'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News24
14 minutes ago
- News24
Looking for the perfect Father's Day gift? Leatherman has two perfect products.
The best tool is something that's small and light enough to be close by when you need it. These two Leathermans will put a sparkle in Dad's eyes. Built tough, sized right The Rebar packs serious capabilities into its slim, 10 cm frame. It weighs less than 190 g but puts 17 essential tools in your pocket, readying you for any task at work or home. That includes: needle-nose pliers, regular pliers, wire cutters, hard-wire cutters, electrical crimper, wire stripper, knife, serrated knife, saw, can opener, bottle opener, wood/metal file, Phillips screwdriver, large and small screwdriver, and a ruler. Its design is classic Leatherman, taking its cues from the original Pocket Survival Tool released in 1983. Rebar features contoured handles for a confident and comfortable grip for security and confidence under demanding conditions. Rebar features all locking tools, so you can apply a lot of pressure, knowing it won't move or fold. Available in Burnt Sienna, and Mossy Slate. Each new Rebar colourway includes a matching nylon sheath. It also has a lanyard ring so that you can take it everywhere with you. The name is Bond . . . Leatherman Bond Inspired by Tim Leatherman's original Pocket Survival Tool, Bond pairs classic design with the tools needed to tackle everyday tasks. At a mere 176 g, this lightweight multi-tool provides 14 essential implements including pliers, a durable 420HC knife blade, and a set of standard screwdrivers. It also has wire cutters, can and bottle opener, and a ruler. All packed into a 10 cm frame (closed length). The Bond's handles are contoured to give you a comfortable grip while using the tools. The colour options add a vibrant Cerakote finish to the handles for increased durability. Cerakote is a thin-film, ceramic-based coating known for its durability, hardness, and scratch resistance. Available in Burnt Sienna, Mossy Slate, and Heathered Cranberry. Each Bond colourway includes a matching nylon sheath. Stainless steel Bond also includes a nylon sheath. For more on these plus other excellent Leatherman products, go to
Bloomberg
40 minutes ago
- Bloomberg
Israel-Backed Gaza Aid Group Suspends Operations for Second Day
An Israel- and US-backed mechanism to distribute food in Gaza suspended operations for a second day following a series of deadly incidents near its sites that drew international criticism. The Gaza Humanitarian Foundation, a Swiss-based nonprofit, launched in Gaza last week following a months-long Israeli blockade of the territory, and says it has handed out enough food staples for millions of meals. But the roll-out has been dogged by overcrowding and at least one incident in which Israeli forces, citing a security threat, fired toward Palestinians headed to a GHF aid center.
Medscape
44 minutes ago
- Medscape
Catching Resistance Early: Can New Breast Cancer Drug Help?
CHICAGO — Can spotting an emerging ESR1 mutation early and changing first-line drugs before progression improve outcomes in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2–negative advanced breast cancer? Interim findings from the SERENA-6 trial suggest that may be the case. Patients who switched from a first-line aromatase inhibitor to camizestrant, an investigational next-generation oral selective estrogen-receptor degrader, at the first signs of an emerging ESR1 mutation demonstrated significantly improved progression-free survival compared with those who continued their initial regimen. Notably, circulating tumor DNA (ctDNA) testing allowed investigators to identify ESR1 mutations, which emerge at the time of disease progression in about 40% of patients on a first-line aromatase inhibitor and lead to treatment resistance. Camizestrant, which has shown activity in patients who develop ESR1 mutations, helped improve first-line outcomes and has 'potential to become a new treatment strategy,' according to co-principal investigator Nicholas Turner, MD, PhD, professor and honorary consultant in medical oncology at the Institute of Cancer Research and Royal Marsden Hospital, London, England, who presented the findings at the American Society of Clinical Oncology (ASCO) 2025 annual meeting. Results were simultaneously published in The New England Journal of Medicine . This trial also demonstrated 'the clinical utility of ctDNA monitoring to detect and treat emerging resistance in breast cancer,' said Turner. While praising the findings, others were not convinced that the SERENA-6 results warrant a change in practice yet. 'Based on first-line progression-free survival alone, this could represent a new regulatory approval path,' said invited discussant Angela DeMichele, MD, of the University of Pennsylvania, Philadelphia. But, DeMichele cautioned, 'I cannot recommend the SERENA-6 strategy at this time.' One key reason, DeMichele noted, is that it's too early to tell whether this strategy improves overall survival. If camizestrant is approved based on progression-free survival and quality of life, DeMichele wondered, is it worth going through the ctDNA testing process if the drug doesn't help patients live longer? Paolo Tarantino, MD, a breast oncologist at Dana-Farber Cancer Institute and Harvard Medical School in Boston, echoed this sentiment in a tweet on X: 'Outstanding results, though not ready for clinical practice (yet),' adding that it will also be 'important to take into account financial, psychological, and systemic costs of the strategy.' Using ctDNA to Track Resistance In the study, 3256 patients who had received at least 6 months of treatment with aromatase inhibitors and CDK4/6 therapy (palbociclib, ribociclib, or abemaciclib) received ctDNA testing with Guardant360 CDx every 2-3 months at the time of routine staging exams. Overall, 315 patients who had an ESR1 mutation detected and had no radiologic evidence of disease progression were randomly assigned to either switch from the aromatase inhibitor to 75 mg of camizestrant daily (n = 157) or continue their aromatase inhibitor/CDK4/6 regimen (n = 158). (An additional 233 patients who had an ESR1 mutation detected were not included for a variety of reasons, including disease progression and consent withdrawal.) At the planned interim analysis, the median progression-free survival was 16.0 months in the camizestrant group and 9.2 months in the aromatase inhibitor group (adjusted hazard ratio [aHR], 0.44; P < .00001). At 24 months, only 5.4% of patients who had continued their initial first-line treatment had not progressed compared with 30% of patients on camizestrant. The progression-free survival findings were consistent across clinically relevant patient subgroups. Patients who switched to camizestrant also showed improved time to deterioration in global health status and quality of life — a median of 23.0 months vs 6.4 months in the aromatase group (aHR, 0.53). At the time of the interim analysis, overall survival data were immature, with 20 deaths in the camizestrant group and 19 in the aromatase inhibitor group (HR, 0.91; 95% CI, 0.48-1.73). As for time to second progression, there were 38 events in the camizestrant group and 47 events in the aromatase group, but the findings were also immature. As for adverse events, 60% of patients in the camizestrant group had a grade 3 or higher event, 10% of which were deemed serious compared with 46% in the aromatase group, 12% of which were serious. Neutropenia (45% vs 34%, respectively) and anemia (5% in both groups) were the most common grade 3 or higher adverse events. Only 1% of patients on camizestrant discontinued treatment due to adverse events. Overall, Turner concluded that 'for people with HR-positive advanced breast cancer, the results of SERENA-6 show that camizestrant plus CDK4/6 inhibitor could be a new treatment option to use at the point of ESR1 mutation detection during treatment with first-line aromatase inhibitor plus CDK4/6 inhibitor — but before the cancer grows.' Despite the promising findings, DeMichele highlighted several key unanswered questions and challenges. Notably, will this strategy lead to longer overall survival and demonstrate clinical utility? Overall survival and time to second progression are currently not known, DeMichele said. The trial did not address whether first-line treatment gains would be lost if camizestrant was given in the second-line setting after anatomic progression. DeMichele also noted the high cost and potential anxiety associated with serial ctDNA testing. Overall, 'the full complement of financial, psychological, and systemic costs is needed to fully assess utility and feasibility for implementation,' she added. SERENA-6 was supported by AstraZeneca. Turner disclosed consulting or advisory roles with AstraZeneca, Exact Sciences, Gilead Sciences, GlaxoSmithKline, Guardant Health, Inivata Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Relay Therapeutics, Repare Therapeutics, and Roche. DeMichele disclosed a consulting or advisory role with Pfizer.
